Popular Trials
HMG-CoA Reductase Inhibitor
Simvastatin for Preventing Liver Cancer in Patients With Cirrhosis
This trial studies if simvastatin can prevent liver cancer in patients with liver cirrhosis. Simvastatin, usually used to lower cholesterol, might block enzymes that cancer cells need to grow. The trial targets patients with liver disease. Simvastatin has been shown to reduce the risk of liver cancer and improve outcomes in these patients.
CFTR Modulator
Lung Perfusion Mapping for Cystic Fibrosis
This trial will use a new MRI method to measure regional lung perfusion in children with CF and relate it to regional assessments of ventilation and to serum cytokines or proteomic markers of angiogenesis and inflammatory processes.
Antioxidant Supplement
Antioxidant Supplements for Cystic Fibrosis
This trial is testing if antioxidant supplements can help people with cystic fibrosis (CF) exercise better. People with CF often struggle with exercise, which can lead to more hospital visits. Antioxidants might help by protecting their cells from damage, making it easier for them to stay active. Glutathione, an antioxidant, has shown potential in improving lung function and reducing oxidative stress in cystic fibrosis patients.
Monoclonal Antibodies
Denosumab for Osteoporosis in Cystic Fibrosis
This trial is testing a new way to treat CF patients with bone disease. Up to 100 subjects with CF will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. If results indicate bone disease, subjects will receive treatment with Denosumab for up to 5 years.
Popular Filters
Trials for Myelofibrosis Patients
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Anti-metabolites
Decitabine for Myelofibrosis
This trial looks at the side effects and effectiveness of decitabine in treating patients with myelofibrosis, a cancer of the blood system. Decitabine may block proteins that turn certain genes off in various cancers including myelofibrosis.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Trials for Idiopathic Pulmonary Fibrosis Patients
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
Trials for CFTR Positive Patients
GLP-1 Agonist
GLP-1 Agonist Therapy for Cystic Fibrosis-related Diabetes
This trial looks at whether a weekly injection of a medication called dulaglutide can help improve early-phase insulin secretion and glucose tolerance in people with cystic fibrosis-related diabetes.
Angiotensin II Receptor Blocker
Losartan for Cystic Fibrosis
This trial is testing losartan, a blood pressure medication, to see if it can help clear mucus from the lungs of cystic fibrosis patients who can't use current treatments. These patients need alternative treatments because they don't respond to existing options. Losartan may reduce lung inflammation, making it easier for them to breathe.
Gene Therapy
Gene Therapy (4D-710) for Cystic Fibrosis
This trial is testing a new gene therapy called 4D-710 in adults with cystic fibrosis who can't use standard treatments. The goal is to see if it is safe and effective. 4D-710 is part of a new generation of AAV vectors being developed for cystic fibrosis gene therapy.
Phase 3 Trials
Galectin Inhibitor
Belapectin for NASH Cirrhosis
This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Statin
Simvastatin for Liver Cirrhosis
This trial tests if simvastatin can prevent serious liver problems in U.S. Veterans with early-stage liver damage. Simvastatin not only lowers cholesterol but also helps protect the liver from further damage and reduces the risk of severe liver issues. Statins, including simvastatin, have been increasingly recognized for their potential benefits in treating chronic liver diseases, including cirrhosis, by reducing portal pressure and protecting against liver damage.
Trials With No Placebo
Behavioural Intervention
Manual Therapy for Swallowing Difficulty in Head and Neck Cancer Survivors
This trial studies the effectiveness of manual therapy (massage and stretching exercises) in treating fibrosis-related dysphagia (difficulty swallowing) in survivors of head and neck cancer.
Cancer Preventive Agent
Green Tea Extract for Liver Cirrhosis
This trial studies the effects of a green tea extract on people with cirrhosis. The goal is to find the best dose and see if it can lower a molecule linked to liver cancer. By reducing this molecule, the treatment may help prevent liver cancer in these patients. Green tea extract has been shown to protect against various forms of liver damage, including those induced by alcohol, acetaminophen, and carbon tetrachloride.
View More Related Trials
Frequently Asked Questions
Introduction to fibrosis
What are the top hospitals conducting fibrosis research?
When it comes to pushing the boundaries in the field of fibrosis research, some leading hospitals are making significant strides. In Boston, renowned for its medical excellence, Boston Children's Hospital is at the forefront with nine active clinical trials focused on fibrosis. With a remarkable 58 completed trials dedicated to this condition since their first recorded trial in 2004, they have established themselves as a powerhouse in advancing our understanding and treatment of fibrosis. The University of Alabama at Birmingham is another prominent institution driving progress with eight ongoing fibrosis trials and an impressive tally of 75 previous studies since their inaugural trial in 2004.
In Kansas City, the University of Kansas Medical Center is actively contributing to combating fibrosis through seven ongoing clinical trials. They have built upon their solid foundation by conducting 52 previous trials since recording their first investigation into fibrosis in 2005. Similarly dedicated to unraveling the mysteries surrounding this condition, Nationwide Children's Hospital in Columbus has seven active clinical trials targeting fibrosis alongside a commendable history of completing 64 previous investigations dating back to their initial work on this topic also starting from around2005.
Lastly but certainly not least important is The Children's Mercy Hospital situated within Kansas City who have made substantial contributions through six ongoing clinical tests specifically designed for tackling various aspects related to Fibrois; having embarked on such journeys only about twelve years ago (in just while before2010). Although considered smaller-scale compared to other institutions mentioned above yet they hold utmost value due dedication demonstrated throughout development eighteen all-time projects till now.
These top-ranking hospitals collectively represent beacons hope for those grappling with Fibrosic conditions; showcasing how collective efforts drive real change towards disease understanding which leads us path-breaking solutions betterment countless lives worldwide
Which are the best cities for fibrosis clinical trials?
Houston, Texas, New york, New York, and Boston, Massachusetts emerge as the leading cities for fibrosis clinical trials. Houston leads the pack with 29 ongoing studies focused on treatments like Inhaled Treprostinil and belapectin. Following closely behind is New York with 28 active trials exploring interventions such as belapectin and Fazirsiran. Boston also plays a significant role in fibrosis research with 27 ongoing trials investigating VX-121/TEZ/D-IVA and ELX/TEZ/IVA. These cities offer individuals with fibrosis access to cutting-edge clinical trials that hold promise for improved treatment outcomes.
Which are the top treatments for fibrosis being explored in clinical trials?
Exciting advancements in fibrosis treatment are being explored through various clinical trials. Leading the way is Saroglitazar Magnesium 2 mg, currently involved in two active trials and holding its ground with two all-time fibrosis trials since it was first listed in 2021. Another promising contender is Losartan, showing potential with two ongoing trials and a total of nine all-time fibrosis studies dating back to 2007. ELX/TEZ/IVA is also making strides, participating in two active trials along with an impressive record of 19 all-time fibrosis trials since its introduction in 2018. Finally, we have Inhaled Treprostinil joining the ranks, engaging in two current research projects after entering the scene just this year alongside four previous fibrosis studies. The dedication shown by these treatments demonstrates their commitment to combating this challenging condition and offering hope to those affected by it
What are the most recent clinical trials for fibrosis?
Exciting advancements are being made in the field of fibrosis treatment, with several recent clinical trials showcasing promising potential. Among them is BMS-986278 Dose 1, which has entered Phase 3 and holds great promise for patients grappling with this condition. Additionally, captopril has shown encouraging results in both Phase 1 and Phase 2 trials, offering hope for improved outcomes in fibrosis management. The efficacy of efzofitimod at a dosage of 450 mg is also under investigation in a Phase 2 study, providing further avenues for exploration. Lastly, rifaximin oral tablets have demonstrated potential benefits as well through their advancement into Phases 2 and 3 trials. These ongoing research endeavors serve as beacons of optimism for individuals affected by fibrosis and offer new possibilities to enhance their quality of life.
What fibrosis clinical trials were recently completed?
A range of clinical trials focusing on fibrosis have recently been completed, showcasing the dedication of researchers in advancing treatments for this condition. Notably, Vertex Pharmaceuticals Incorporated sponsored several trials: ELX/TEZ/IVA concluded in May 2022 and was also completed in January 2022 and November 2020. Nabriva Therapeutics AG's trial investigating Lefamulin finished in March 2022, while Insmed Incorporated's Brensocatib trial wrapped up in November 2021. Stanford University conducted a trial involving Empagliflozin 10 MG that ended in November 2021 alongside University of Michigan's investigation into Lactulose. AbbVie-sponsored CREON concluded its trial in October 2021. Additional studies include those by Armata Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, NGM Biopharmaceuticals, Inc., Pliant Therapeutics, Inc., Vertex Pharmaceuticals Incorporated (LUM/IVA), and St. Louis University (SmartPill Motility System & PillCam Patency Capsule). These recent breakthroughs offer hope for patients affected by fibrosis.